Full-Time
Commercial Counsel Director
Updated on 9/4/2026
Mirum Pharmaceuticals
201-500 employees
ASBT inhibitors for rare liver diseases
Compensation Overview
$250k - $275k/yr
San Mateo, CA, USA
Hybrid
Hybrid role; on-site presence in Foster City, California required.
JD
 Legal (1) |
|---|
Get referred to Mirum Pharmaceuticals
See people who can refer or advise you
- J.D. and licensed to practice law in at least one U.S. jurisdiction (active and in good standing)
- 6+ years of relevant legal experience, including meaningful in-house and/or law firm experience supporting life sciences or biopharmaceutical companies
- Strong understanding of healthcare regulatory and compliance frameworks that apply to commercial biopharmaceutical companies
- Excellent written and oral communication skills, with the ability to translate complex legal concepts into clear, practical guidance
- Keen to embrace and understand all areas of the law relevant to the in-house practice of a pharmaceutical lawyer
- Strong commercial acumen, legal drafting skills, and presentation skills
- An ability to work as a member of an international team
- Support the company’s commercial organization, including promotional material review, commercial effort/program risk assessment, and providing counsel and guidance on advertising, promotional, sales and marketing assessments
- Draft, review, and negotiate a broad range of commercial agreements, including grants and corporate giving, license, payor/government pricing and commercial enablement
- Help maintain and enhance commercial policies, procedures, and internal controls
- Provide legal support for commercial growth activities, including named patient programs and distribution efforts
- Partner cross-functionally with Commercial, Regulatory, Finance, and HR teams to structure and negotiate agreements aligned with commercial objectives
- Identify and mitigate legal risks while providing guidance on FDA and OIG regulations and industry codes
- Advise on healthcare, regulatory, and compliance matters relevant to a biopharmaceutical company, including promotional review, transparency laws, and interactions with healthcare professionals/patient advocacy groups
- Support development and implementation of Patient and Healthcare Providers interaction policies and training initiatives
- Assist in managing internal investigations and responding to regulatory inquiries, as needed
- Contribute to risk assessments and mitigation strategies across the organization
- Help manage outside vendor relationships with attention to adherence to industry transparency codes, quality, efficiency, and cost management
- Help enforce and train on company-wide understanding of privacy laws and regulations as it relates to Company’s commercial footprint, such as the GDPR and CCPA, and assist the VP-Legal with monitoring regulatory changes, industry trends, and emerging technologies
- Advise the organization on how to comply with privacy laws and regulations, including best practices for data collection, storage, and sharing
- Serve as a trusted legal advisor to internal stakeholders across departments
- Provide timely, practical, and solutions-oriented legal advice across a broad range of commercial, corporate, and operational matters
- Develop scalable legal processes appropriate for a growing global organization
- Promote a culture of integrity, accountability, and compliance
- Understanding of privacy laws and regulations preferred but not required
Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases. Its lead drug LIVMARLI (maralixibat) is an oral ASBT inhibitor that lowers bile acid buildup to relieve itching in cholestatic conditions such as Alagille syndrome, and the company is pursuing LIVMARLI for additional rare liver diseases, with volixibat as another ASBT inhibitor in its pipeline. The company differentiates itself by focusing on rare pediatric and adult cholestatic diseases and building dedicated commercialization infrastructure in the U.S. and other major markets, including partnerships with physicians, payers, and patient groups to improve patient access. Mirum’s goal is to bring effective therapies to patients with rare bile-duct and liver disorders, expand LIVMARLI indications, and establish a sustainable market presence in key markets.
Company Size
201-500
Company Stage
IPO
Headquarters
Foster City, California
Founded
2018
Get referred to Mirum Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 net product sales reached $176.2 million, and guidance rose to $700 million.
- Rob Myers starts September 21, 2026, strengthening hepatology leadership before key readouts.
- Volixibat, brelovitug, and zilurgisertib create multiple catalysts through first-half 2027.
What critics are saying
- FDA recommended another volixibat Phase 3 on August 5, 2026, delaying PSC filing.
- If LIVMARLI growth slows, Mirum loses the cash engine funding its pipeline.
- Zilurgisertib’s September 26, 2026 PDUFA denial would crush sentiment and financing flexibility.
What makes Mirum Pharmaceuticals unique
- LIVMARLI dominates rare pediatric cholestatic disease with expanding PFIC and biliary atresia labels.
- Mirum combines commercialization strength with late-stage hepatology pipeline breadth across PSC, HDV, and FOP.
- Exclusive zilurgisertib rights from Incyte add a near-term rare-disease launch platform.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↑ 0%Mirum Pharmaceuticals has appointed Dr Rob Myers as chief medical officer, effective 21 September 2026. Dr Myers will lead the company's global medical and clinical development functions. Dr Myers brings over 20 years of experience in drug development, with particular expertise in hepatology. He joins from OrsoBio, where he served as chief medical officer and head of development. Previously, he held senior leadership positions at Gilead Sciences, overseeing clinical development programmes across liver fibrosis, cholestatic liver diseases, and gastrointestinal inflammation. Dr Myers has published more than 200 peer-reviewed papers and has contributed to advancing understanding of primary sclerosing cholangitis. He holds an MD from Western University and a master's degree in epidemiology from the University of Calgary.
US FDA approves Regeneron's rare bone disorder drug. Regeneron's Pasatru has received US FDA approval for adults with FOP after clinical trials showed a significant reduction in abnormal bone formation. By Reuters August 20, 2026, 8:59:40 AM IST (Published) The US FDA on Wednesday (August 19) approved Regeneron's drug for a rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues. New York-based Regeneron's shares rose 4%. The drug, garetosmab, branded as Pasatru, was approved to treat adults with fibrodysplasia ossificans progressiva (FOP) - a condition in which muscle, tendon and ligament tissue gradually turns into bone, leading to a "second skeleton" that causes progressive loss of mobility and reduced life expectancy. In a 56-week trial involving 63 participants, Pasatru reduced the development of new bone abnormalities by 94% in patients treated with a 3 mg per kg dose and by 90% in those given a 10 mg per kg dose, compared with a placebo. The drug works by blocking Activin A, a protein involved in triggering abnormal bone growth in patients with FOP. Susan Rhee, a member of Regeneron's clinical team, told Reuters last week that the company plans to start a trial for children later this year. The drug will compete with French drugmaker Ipsen's oral treatment Sohonos, which in 2023 became the only other treatment approved by the US Food and Drug Administration. Incyte and partner Mirum Pharma, as well as privately held Ashibio, are also developing treatments for the condition. In 2020, Regeneron paused dosing in a mid-stage trial of the drug after five patient deaths, ultimately discontinuing the study and working with global regulators to design the late-stage trial, according to the company. The condition affects roughly 1 in 2 million people worldwide, with around 800 to 900 active diagnosed cases globally, according to data from the National Institutes of Health.
Mirum Pharmaceuticals shares plunged 15% on Thursday after the FDA recommended an additional Phase 3 study for its liver disease candidate Volixibat, potentially delaying the new drug application until the first half of 2027. Citizens lowered its price target to $137 from $146 whilst maintaining an Outperform rating. The regulatory setback overshadowed strong second-quarter results. Mirum reported revenue of $176.2 million, beating analysts' estimates of $167.3 million. The company raised its full-year net product sales guidance to $680 million to $700 million, from $660 million to $680 million. Mirum ended the quarter with $561.3 million in cash and equivalents. Volixibat has already received FDA Breakthrough Therapy and Orphan Drug designations.
Mirum Pharmaceuticals raised its full-year 2026 net product sales guidance to $680 million to $700 million, citing growth in Alagille syndrome and expanding adult PFIC diagnosis. The company secured $690 million through a convertible note offering, improving its capital structure whilst settling 75% of 2029 notes. The firm identified a significant opportunity in adult PFIC, estimating at least 2,000 addressable patients each in the US and Europe. Commercial operations achieved a high-50s percent cash contribution margin, representing a 5 percentage point year-over-year improvement. Mirum delayed its volixibat PSC NDA submission due to alignment issues with FDA reviewers but received Breakthrough Therapy Designation. The company targets a first-half 2027 NDA submission for PSC and anticipates Phase III PBC results in Q1 2027.
Mirum Pharmaceuticals reported revenue of $176.24 million for the quarter ended June 2026, up 37.9% year-over-year. The figure exceeded the consensus estimate of $164.76 million by 6.97%. The company posted a loss of $0.80 per share, compared to $0.12 a year ago, slightly missing the estimated loss of $0.77 per share. Product sales showed strong performance across categories. Livmarli generated $128.72 million, surpassing the $119.6 million analyst estimate. Bile acid medicines brought in $47.52 million, also beating expectations of $45.64 million. Despite beating revenue estimates, Mirum's shares fell 18.7% over the past month, underperforming the S&P 500's 3.5% gain.